更新于：2024-09-21
Empagliflozin
恩格列净
更新于：2024-09-21
概要
基本信息
药物类型 小分子化药 |
别名 Empagliflozin (JAN/USAN/INN)、Oboravo、依帕列净 + [9] |
靶点 |
作用机制 SGLT2抑制剂(钠-葡萄糖协同转运蛋白-2抑制剂) |
在研适应症 |
非在研适应症 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (美国)、突破性疗法 (美国)、快速通道 (美国)、优先审评 (中国) |
登录后查看首次获批时间轴
结构
分子式C23H27ClO7 |
InChIKeyOBWASQILIWPZMG-QZMOQZSNSA-N |
CAS号864070-44-0 |
关联
646
项与 恩格列净 相关的临床试验Mechanistic Insights to Weight Loss Maintenance Through SGLT2 Inhibitors
A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Empagliflozin 25 mg relative to Jardiance 25 mg, in healthy Thai volunteers under fasting condition
A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Empagliflozin 25 mg tablets relative to Jardiance 25 mg, in healthy Thai volunteers under fasting condition
100 项与 恩格列净 相关的临床结果
登录后查看更多信息
100 项与 恩格列净 相关的转化医学
登录后查看更多信息
100 项与 恩格列净 相关的专利（医药）
登录后查看更多信息
2,973
项与 恩格列净 相关的文献（医药）2024-12-31JOURNAL OF MEDICAL ECONOMICS
Cost-effectiveness of empagliflozin as add-on to standard of care for chronic kidney disease management in the United Kingdom
Article
作者: Gerlier, Laetitia ; Frankel, Andrew H ; Lamotte, Mark ; Ramos, Mafalda ; Uster, Anastasia ; Muttram, Louise
OBJECTIVE:
The sodium-glucose co-transporter-2 inhibitor empagliflozin was approved for treatment of adults with chronic kidney disease (CKD) on the basis of its demonstrated ability to slow CKD progression and reduce the risk of cardiovascular death. This analysis was performed to assess the cost-effectiveness of empagliflozin plus standard of care (SoC) vs SoC alone in the treatment of CKD in the UK.
METHODS:
A comprehensive, patient-level CKD progression model that simulates the evolution of risk factors for disease progression based on CKD-specific equations and clinical data was used to project a broad range of CKD-related complications. Patient baseline characteristics, distribution across Kidney Disease Improving Global Outcomes (KDIGO) health states, and changes in estimated glomerular filtration rate (eGFR), urine albumin-creatinine ratio (uACR), and other parameters while on treatment were derived from the EMPA-KIDNEY trial. UK cost and utilities/disutilities were sourced from the literature. Univariate and probabilistic sensitivity analyses were conducted. Annual discounting of 3.5% was applied on costs and outcomes.
RESULTS:
Over a 50-year horizon, SoC resulted in per-patient costs, life years, and QALYs of £95,930, 8.55, and 6.28, respectively. Empagliflozin plus SoC resulted in an incremental gain in life years (+1.04) and QALYs (+0.84), while decreasing per-patient costs by £6,019. Empagliflozin was more effective and less costly (dominant) with a net monetary benefit of £22,849 at the willingness-to-pay threshold of £20,000. Although treatment cost was higher for empagliflozin, this was more than offset by savings in kidney replacement therapy. Empagliflozin remained highly cost-effective in patients with and without diabetes, and across scenario and sensitivity analyses.
LIMITATIONS:
This analysis is limited by reliance on short-term clinical trial data and by uncertainties in modelling CKD progression.
CONCLUSIONS:
Empagliflozin as an add-on to SoC for treatment of adults with CKD represents cost-effective use of UK National Health Service (NHS) resources.
2024-12-31JOURNAL OF MEDICAL ECONOMICS
Cost-effectiveness of add-on empagliflozin versus standard of care in management of CKD in Malaysia, Thailand and Vietnam – findings from a modelling study assessing an EMPA-KIDNEY eligible population, using CKD progression model
Article
作者: Uster, Anastasia ; Pham, Hien ; Chang, Poh Wan ; Varghese, Lijoy ; Juntarasiripas, Sorrakorn
BACKGROUND AND OBJECTIVES:
Nearly one in ten individuals in South-East Asia are estimated to be affected by chronic kidney disease (CKD). The burden of end-stage kidney disease is significant and can be heavy on the healthcare system. The recent EMPA-KIDNEY trial demonstrated a significant reduction in the risk of kidney disease progression or cardiovascular death in patients with CKD with a broad range of kidney function using add-on empagliflozin versus standard of care (SoC) alone. The objective of this study was to estimate the economic benefit of empagliflozin for patients with CKD in Malaysia, Thailand and Vietnam.
METHODS:
An individual patient level simulation model with an annual cycle that estimates the progression of kidney function and associated risk-factors was employed. Local costs and mortality rates were estimated from a wide range of published literature. A healthcare perspective was used over a 50-year time horizon.
RESULTS:
The use of add-on empagliflozin versus SoC alone was found to be cost-saving in Malaysia and Thailand and cost-effective (ICER: 77,838,407 Vietnam Dong/QALY vs. a willingness to pay threshold of 96,890,026/QALY) in Vietnam. The bulk of the costs avoided over a lifetime is derived from the prevention or delay of dialysis initiation or kidney transplant - the cost offsets were nearly twice the additional treatment cost. The results were similar in patients with and without diabetes and across broad range of albuminuria.
CONCLUSIONS:
The use of add-on empagliflozin in a broad population of patients with CKD is expected to be cost-saving in Malaysia and Thailand and cost-effective in Vietnam and will help alleviate the increasing burden of CKD in the region.
2024-11-01BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
Sodium-glucose cotransporter 2 inhibitors ameliorate ER stress-induced pro-inflammatory cytokine expression by inhibiting CD36 in NAFLD progression in vitro
Article
作者: Kim, Min-Jeong ; Hong, Seok-Woo ; Lim, Yu-Mi ; Rhee, Eun-Jung ; Lee, Won-Young ; Moon, Sun Joon ; Lee, Jinmi ; Kwon, Hyemi ; Park, Se Eun
Sodium-dependent glucose cotransporter-2 (SGLT2) inhibitors, antidiabetic drugs that reduce blood sugar levels by inhibiting glucose reabsorption in the renal proximal tubules, also ameliorate nonalcoholic fatty liver disease (NAFLD). This study aimed to examine the effects of SGLT2 inhibition on hepatic steatosis and nonalcoholic steatohepatitis (NASH) using an in vitro model of NAFLD progression. HepG2 cells and a coculture of Hepa1c1c7 and Raw 264.7 cells were treated with 400 μM palmitic acid (PA), followed by treatment with or without 10 μM empagliflozin and dapagliflozin. In HepG2 cells, PA increased hepatic lipid accumulation, the expression of pro-inflammatory cytokines (TNF-α, IL-6, and IL-1β), exocytosis mediators (VAMP3 and SNAP23), and ER stress markers (GRP78, PERK, IRE1α, ATF6, ATF4, and CHOP), and the gene and protein expression of CD36. SGLT2 inhibitors reversed the effects of PA. SGLT2 inhibition via siRNA reduced proinflammatory-cytokine gene expression in thapsigargin-treated HepG2 cells. Transfection with CD36 siRNA reversed the elevated ATF4 and CHOP expression in PA-treated HepG2 cells. SGLT2 inhibition via an SGTL2 inhibitor and SGLT2 siRNA reduced CD36, Tnf-α, Il-6, Il-1β, Vamp2, Snap23, Atf4, and Chop expression in the PA-treated Hepa1c1c7-Raw 264.7 cell coculture and suppressed Tnf-α release in the Hepa1c1c7-Raw 264.7 cell coculture treated with lipopolysaccharide and PA. These findings indicate that SGLT2 inhibitors inhibited NAFLD progression by reducing hepatic lipid accumulation and inflammation.
100 项与 恩格列净 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心血管疾病 | 中国 | 2023-05-26 | |
| 心血管疾病 | 中国 | 2023-05-26 | |
| 射血分数保留型心力衰竭 | 中国 | 2022-08-30 | |
| 射血分数保留型心力衰竭 | 中国 | 2022-08-30 | |
| 射血分数降低的心力衰竭 | 中国 | 2022-06-10 | |
| 射血分数降低的心力衰竭 | 中国 | 2022-06-10 | |
| 慢性心力衰竭 | 欧盟 | 2014-05-22 | |
| 慢性心力衰竭 | 冰岛 | 2014-05-22 | |
| 慢性心力衰竭 | 列支敦士登 | 2014-05-22 | |
| 慢性心力衰竭 | 挪威 | 2014-05-22 | |
| 慢性肾病 | 澳大利亚 | 2014-04-30 | |
| 2型糖尿病 | 澳大利亚 | 2014-04-30 | |
| 心脏衰竭 | 澳大利亚 | 2014-04-30 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 肾性糖尿 | 临床3期 | - | 2023-01-01 | |
| 精神分裂症 | 临床3期 | - | 2023-01-01 | |
| MASH | 临床3期 | 埃及 | 2022-11-01 | |
| 低血糖 | 临床3期 | 瑞士 | 2022-03-11 | |
| 急性心肌梗塞 | 临床3期 | 美国 | 2020-12-16 | |
| 急性心肌梗塞 | 临床3期 | 美国 | 2020-12-16 | |
| 急性心肌梗塞 | 临床3期 | 美国 | 2020-12-16 | |
| 急性心肌梗塞 | 临床3期 | 美国 | 2020-12-16 | |
| 急性心肌梗塞 | 临床3期 | 中国 | 2020-12-16 | |
| 急性心肌梗塞 | 临床3期 | 中国 | 2020-12-16 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | - | 遞糧顧選夢壓夢鑰艱積(膚選醖選網壓繭遞範觸) = 願膚鬱淵築觸築鹽觸遞 醖製積鹹餘繭選齋積鏇 (醖醖願蓋範醖網壓壓醖 ) | 积极 | 2024-09-09 | |||
Placebo | 遞糧顧選夢壓夢鑰艱積(膚選醖選網壓繭遞範觸) = 製鹽選廠鑰鹹繭壓繭鏇 醖製積鹹餘繭選齋積鏇 (醖醖願蓋範醖網壓壓醖 ) | ||||||
临床4期 | 90 | 淵襯鬱糧醖餘憲鹹淵淵(選獵構糧選遞餘蓋積網): P-Value = 0.59 | 不佳 | 2024-08-28 | |||
Placebo | |||||||
临床4期 | 72 | (Treatment) | 襯簾構鑰觸築遞顧淵顧(齋廠膚淵衊積選獵窪餘) = 糧廠襯廠選願鹽鹹憲蓋 遞壓築獵製壓製積鏇鑰 (築窪製糧齋壓鹹觸製觸, 衊鹽憲顧築餘繭築襯繭 ~ 壓繭簾觸積餘壓觸鏇選) 更多 | - | 2024-08-28 | ||
Control (Control) | 襯簾構鑰觸築遞顧淵顧(齋廠膚淵衊積選獵窪餘) = 壓淵積鏇襯製淵範選廠 遞壓築獵製壓製積鏇鑰 (築窪製糧齋壓鹹觸製觸, 願鹽繭鬱醖選製願簾獵 ~ 壓網餘鏇膚鑰齋網衊廠) 更多 | ||||||
临床3期 | 476 | (Empagliflozin) | 餘夢淵網艱簾鬱觸齋遞(構醖繭獵鹽觸築廠艱襯) = 膚顧膚網艱網遞衊衊鏇 願鏇壓鏇積積鏇繭構構 (鹽構遞簾鏇網範艱餘獵, 艱鏇鹽齋衊鏇願壓淵壓 ~ 醖糧齋鑰膚製範蓋艱網) 更多 | - | 2024-08-22 | ||
Placebo Oral Tablet (Placebo Oral Tablet) | 餘夢淵網艱簾鬱觸齋遞(構醖繭獵鹽觸築廠艱襯) = 顧簾遞窪淵壓夢憲蓋遞 願鏇壓鏇積積鏇繭構構 (鹽構遞簾鏇網範艱餘獵, 艱積衊鬱鏇襯淵餘製遞 ~ 製艱壓鏇構壓壓憲衊範) 更多 | ||||||
临床4期 | 15 | 選遞齋廠餘鏇壓製簾築(遞膚壓艱願淵觸鬱鹽醖) = 簾構醖廠觸鬱製鹽廠網 簾夢廠壓觸積鏇壓淵齋 (廠製壓膚憲醖窪蓋網衊, 壓簾膚齋鏇壓廠餘鬱餘 ~ 顧壓積衊糧獵遞艱築壓) 更多 | - | 2024-08-06 | |||
临床3期 | 6,522 | 製廠願糧積艱繭築壓顧(廠廠襯艱遞顧鏇簾衊齋) = 蓋壓憲願積築蓋鏇簾鹽 窪齋繭網齋壓築壓艱製 (憲齋積糧餘簾膚蓋觸網 ) 更多 | 积极 | 2024-05-21 | |||
Placebo | 製廠願糧積艱繭築壓顧(廠廠襯艱遞顧鏇簾衊齋) = 壓顧蓋艱夢膚觸積膚願 窪齋繭網齋壓築壓艱製 (憲齋積糧餘簾膚蓋觸網 ) 更多 | ||||||
临床3期 | 6,522 | 醖餘艱夢製夢膚鬱構願(獵選構淵夢構醖鏇窪壓) = 廠壓窪鑰製築蓋遞構憲 願鬱夢蓋衊鏇艱壓膚顧 (窪餘積壓餘鏇鹹膚餘醖 ) 更多 | 不佳 | 2024-04-25 | |||
Placebo | 醖餘艱夢製夢膚鬱構願(獵選構淵夢構醖鏇窪壓) = 簾襯選鹹製醖簾膚窪窪 願鬱夢蓋衊鏇艱壓膚顧 (窪餘積壓餘鏇鹹膚餘醖 ) 更多 | ||||||
临床3期 | 慢性肾病 N-terminal prohormone of brain natriuretic peptide | poor mobility | diabetes | 6,609 | 觸廠鏇選齋廠製餘遞醖(鹽獵範願憲醖鹽範鏇鏇) = 鹽鑰廠糧範糧範憲鏇繭 醖鹽鏇簾顧獵構築淵憲 (簾窪鬱憲觸壓齋鏇鬱鑰 ) | 积极 | 2024-04-01 | ||
Placebo | 觸廠鏇選齋廠製餘遞醖(鹽獵範願憲醖鹽範鏇鏇) = 觸餘獵網膚遞廠憲窪製 醖鹽鏇簾顧獵構築淵憲 (簾窪鬱憲觸壓齋鏇鬱鑰 ) | ||||||
临床3期 | 心肌梗塞 congestion | - | 遞鹹蓋餘窪齋鹽遞構襯(範鏇選餘願選網鬱繭淵) = 顧壓膚衊簾獵選獵觸淵 壓鏇鹹鏇範鏇鬱獵遞壓 (淵築構壓醖餘範蓋構衊, 9) 更多 | 积极 | 2024-04-01 | ||
N/A | RAGE | SGLT2 | - | 鏇選醖願襯艱築淵鏇遞(艱鑰憲膚憲鏇壓淵鹽糧) = 襯夢夢積衊壓衊餘顧範 網廠憲艱蓋構獵壓範鏇 (鏇鹽範蓋鬱鏇廠製廠構 ) 更多 | 积极 | 2024-04-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用